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Abstract: The prevalence of drug resistance has become an important issue 
in various yeast infections, which have a significant effects on both human 
animal health. In this study, an attempt has been made to determine 
susceptibility pattern of two antifungal agents Terbinafine and Ketoconazole 
against 45 oral and non oral Candida albicans isolates using broth 
microdilution method. Under in vitro conditions, results showed that (42/45) 
93% of the C. albicans isolates had MIC values indicating susceptibility to 
Ketoconazole (≤0.125 μg/ml) and MICs ranged from ≤0.03125-8.0 μg/ml. 
According to Terbinafine, (40/45) 88.9% of isolates had MICs less than 4 
μg/ml and MICs ranged from 0.25-8.0 μg/ml. This is the first report of in vitro 
antifungal susceptibility data to be published from Palestine against clinical 
isolates of Candida albicans. Availability of sensitive and highly accurate 
antifungal susceptibility testing methods, can permit analysis of data in vitro 
and with outcome in vivo, important  to assist physician for making 
appropriate drug choices and patient management decision. These data 
indicated that Terbinafine and Ketoconazole are still active against C. albicans 
and may therefore have clinical applications against some of these organisms. 




 مسألة في غاية األهمية تعتبر المهجريةالكائنات الحية  بين مقاومة الدواءانتشار  إن :الملخص
في  .والحيوان اإلنسان كبيرة على صحة  سلبيةتأثيرات  لها أصبح، والتي الفطريةتاللتهابالبالنسبة 
 كيتوكونازول تربينافين و العالجات الفطرية هما ثنين من الالحساسية نمط  تحديدتم قد، فهذه الدراسة
باستخدام  و ذلك ةالفموي وغير ةالفموي (Candida albicans)  عزلة من المبيضة البيضاء 45 ضد
  أظهرت تجارب المختبر (Broth Microdilution Method).التخفيف الدقيق المتسلسل  طريقة
لها  المثبط الحد األدنى تركيز قيم كانت  المبيضة البيضاءتعزال  من 93% (42/45) أن
(Minimum Inhibitory Concentration (MIC)) المبيضة البيضاء  حساسيةإلى تشير 
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 0.03125≤ بين المثبط الحد األدنى تركيز قيم تراوحت ، و)مل/ميكروغرام (≤0.125لكيتوكونازول
عزالت المبيضة البيضاء  من 88.9% (40/45)   فإنلتربينافيننسبة بالأما. مل / ميكروغرام 8.0-
 الحد األدنى تركيز قيم وتراوحت مل / ميكروغرام 4أقل من   المثبط لهاالحد األدنى تركيز قيم كانت
 عن من فلسطين يتم نشره قريرت  أولهذا هو يعتبر . مل  / ميكروغرام  8.0 - 0.25  بينالمثبط
اختبار   لفحصدقيقة للغايةحساسة وطرق  توافر إن .المبيضة البيضاء من ةيسرير عزالت حساسية
  .بشكل صحيح المريض مراقبة حالة و اختيار العالج المناسب  على الطبيب يساعد، الحساسية
المبيضة  ضد نفعاال ن عالجانزااليال  كيتوكونازول  وتربينافين المضادان  أنإلى النتائج وأشارت
 .البيضاء
 الحد األدنى تركيز ،كيتوكونازول ،تربينافين ،ةلفطريات امضادال،المبيضة البيضاء : الدالةالكلمات
  .المثبط
Introduction: 
Recently, several new antifungal agents have become important and available 
for both the topical and systemic treatment of fungal infections. Most antifungal 
drugs have adverse side effects, broad prophylactic usages and long-term 
treatments with those agents become ineffective against some fungi, and lead to 
development of resistance. The prevalence of drug resistance has become a 
serious issue in various yeast infections, which has a significant effects on 
human health [1,2]. 
Candida albicans is considered one of the most frequently implicated pathogen, 
causing localized, invasive or disseminated disease in normal or 
immunocompromised hosts, promoted by the use of broad spectrum antibiotic, 
steroids or other immunosuppressive drugs, diabetes mellitus, AIDS, cancer 
chemotherapy and organ transplantation etc. Candida infection is involving 
every part of the body and is considered the fourth most prevalent organism 
found in blood stream infections. C. albicans represents more than 80% of 
isolates recovered from clinical infection [3,4]. In addition to that, rarely other 
Candida species can cause infection. The importance of Candida species is not 
only due to the severity of their infections but also due to their ability to 
develop resistance against antifungal drugs. In vitro antifungal susceptibility 
testing plays an increasingly important role in guiding the selection of 
antifungal therapy, as an aid in drug development studies, and to detect shifts 
toward resistance as early as possible in epidemiologic studies [5-7]. Although 
Candida species have various degrees of susceptibility to frequently used 
antifungal agents, antifungal resistance is rare [8]. Antifungal susceptibility 
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testing is not routinely done in Palestine as well as in other countries, mainly 
due to economic resources are very limited and low demand. By performing 
antifungal susceptibility testing, this will avoid unnecessary usage of antifungal 
agents and more importantly, the patients do not have to bear the unnecessary 
side effects or toxicity of these antifungal agents. The changing epidemiology 
of Candida infections and the increase in serious fungal infections, the 
emergence of resistant Candida strains and the availability of new antifungal 
agents can assist in their clinical use, may influence the choice of antifungal 
agents for the patients [9]. In this study, an attempt has been made to determine 
susceptibility pattern of two antifungal agents (Terbinafine and Ketoconazole) 
against 45 oral and non oral Candida albicans isolates using broth microdilution 
method. 
Materials and Methods: 
Candida albicans isolates: 
A total of forty-five clinical isolates of C. albicans were recovered from various 
clinical specimens during the 2008-2009. The specimens used in this study 
included 27 oral isolates while the rest of the non-oral isolates. These isolates 
were identified by phenotypic characteristics. C. albicans isolates were 
differentiated from other Candida and Cryptococcus species by their ability to 
grow on the Levine formula of EMB agar and to produce germ tubes within 3 
hours, and pseudohyphae and budding cells at 18-24 hours when incubated at 
35oC in 5-10% CO2. The addition of tetracycline to the Levine formulation aids 
in the selection of C. albicans from clinical sources that are contaminated with 
bacteria. A reference strain (C. albicans ATCC 10231) was also included. 
Antifungal Susceptibility Testing  
Antifungal susceptibility of C. albicans isolates was tested by the broth 
microdilution technique with endpoints read at 48 hours as standardized by the 
Clinical and Laboratory Standards Institute (CLSI), formerly the National 
Committee for Clinical Laboratory Standards [10]. Antifungal agents including 
Terbinafine and Ketoconazole were used -as commercially supplied- to prepare 
solutions of a concentration 128 μg/ml. Minimum inhibitory concentration 
(MIC) was determined in RPMI 1640 medium (Sigma) buffered to pH 7.0 with 
0.165 M morpholinopropansulfonic acid (MOPS) buffer (Sigma). 
Determination of MIC was performed in 96-wells microtiter plates, which were 
inoculated with 1 x 104/ml of C. albicans isolates and incubated at 35ºC for 48 
h. The final concentrations of the antifungal agents were 64 to 0.03125 μg/ml 
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for all antifungal agents. Control wells drug-free were also included in the 
study. All the testing was done in duplicates. 
Results: 
A total of 45 isolates were analyzed for their susceptibilities to Ketoconazole and 
Terbinafine. In-vitro susceptibility data for all isolates tested against these two 
antifungal agents are summarized in Table 1. Ketoconazole was highly active, 
our results showed that (42/45) 93% of the C. albicans isolates had MIC values 
indicating susceptibility to Ketoconazole (≤0.125 μg/ml) and MICs ranged from 
≤0.03125-8.0 μg/ml. According to Terbinafine no specific breakpoints 
proposed, but (40/45) 88.9% of isolates had MICs less than 4 μg/ml and MICs 
ranged from 0.25-8.0 μg/ml. The geometric mean MIC values were ≤0.054 
μg/ml and 2.52 μg/ml for Ketoconazole and Terbinafine, respectively. C. 
albicans ATCC 10231 had MICs ≤0.03125 μg/ml and 16 μg/ml against 
Ketoconazole and Tterbinafine, respectively. 
Table 1. Minimum Inhibitory Concentrations (MICs) and Geometric Mean 








































Prolonged or repeated exposure to antifungal drugs may be associated with the 
emergence of antifungal resistance among strains of C. albicans. The 
determination of the in vitro susceptibility may prove helpful to predict the 
ability of a given antifungal agent to eradicate Candidal isolates. In our work, 
the evaluation of in vitro susceptibility showed that the antifungal drugs tested 
(Ketoconazole and Terbinafine) displayed a high activity against the C. albicans 
isolates. It is worth mentioning that both Ketoconazole and Terbinafin had low 
MIC and geometric mean MIC values. These low MICs found for the these two 
drugs can help to explain the promising results obtained for the treatment of C. 
albicans with these antifungal agents.  
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Terbinafine is the only systemic allylamine antifungal agent currently available, 
which presents a potent in vitro activity against a number of filamentous and 
dimorphic fungi. Some researchers have proposed the application of this agent 
against Candida yeasts [11]. Although, its capacity to inhibit yeasts is still 
controversial. Clinically relevant interpretive breakpoints are not currently 
available for Terbinafine, but in our study no isolates with higher MICs (>8 
μg/ml) was observed. Our results showed that geometric mean MIC value for 
Terbinafine against C. albicans isolates is consistent with previous report [12],  
which showed that geometric mean MIC value for Terbinafine against C. 
albicans was 2.83 μg/ml. These results were in agreement to reports published 
previously [11,13], who obtained good results for Tterbinafine against Candida 
spp. isolates. However, these results are in contrast to a previous report [12], 
who showed that Terbinafine had high MIC values for all Candida spp. 
evaluated  (MIC90 ≥ 64.0 μg/ml). Patients in previous study might have a 
history of antifungal use or ever unknown the name or function of a medicine 
prescribed. 
Earlier susceptibility testing of Terbinafine against yeasts showed poor activity 
[15,16], while more recent studies have shown that this drug is clearly effective 
in inhibiting yeasts [12,13,17]. This is not a surprise due to wide differences 
existed in the methodologies used to evaluate in vitro activity of Terbinafine by 
earlier researchers [11,12]. In contrast to earlier studies, the NCCLS 
macrodilution assay shows reproducible in vitro data for Terbinafine against 
Candida and other yeasts [10]. Interestingly, in the present study the MICs of 
Terbinafine against C. albicans were much lower than those obtained by earlier 
workers [18-21]. They reported high MICs around 25 μg/ml for C. albicans, 
while in the present study, MIC has ranged from 0.03125–8.0 μg/ml for C. 
albicans. Our results were consistent with that reported previously [12], which 
showed that MIC has ranged from 0.03125–4 μg/ml for C. albicans. This may 
be likely due to using medium is buffered at neutral pH, which provide good 
results for Terbinafine. While earlier assays used unbuffered media which are 
rapidly acidified by Candida spp., led to the recording of high MIC values 
which means that the Terbinafine is much less active at low pH [22,23]. So it 
was suggested that buffer MOPS should be added to the culture medium since 
Terbinafine is less effective under low pH conditions as an essential 
prerequisite for testing antifungal activity against yeasts. The in vitro activity of 
Terbinafine against C. albicans is thus of interest with regard to potential 
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clinical efficacy. Clinical studies have shown that topical and oral Terbinafine 
formulations are active against cutaneous candidiasis and Candida nail 
infections [13,24]. 
According to Ketoconazole, our results were inconsistent with studies carried 
out previously [25-27]. It was shown that 80.3% (57/71) of C. albicans isolates 
were sensitive to Ketoconazole (MIC ≤ 0.03-4 μg/ml) and 19.7% (14/71) were 
intermediate susceptibility (MIC 16-32 μg/ml ) to Ketoconazole [25]. C. 
albicans isolated from blood culture of cancer patients showed 28/56 (50%) of 
isolates were sensitive (MIC ≤0.125-4), 22/58 (39.3%) were intermediate (MIC 
16-32) and 6/58 (10.7%) were resistant (MIC≥64) against Ketoconazole [26]. In 
other study it was found that MIC90 of Ketoconazole for all C. albicans isolated 
from the oral cavities of AIDS patients were >32 μg/mL with a range from 
0.064->32 μg/mL [27], this high resistance may be explained by the 
phenomenon of cross-resistance observed among the family of azole 
compound. Besides, the selection of resistant isolates to azoles would be 
explained by the long term of azoles in the prophylaxis therapy for patients with 
AIDS or other immunosuppressive diseases. Our results were in accordance 
with the previous results which showed that 93% of C. albicans were sensitive 
to Ketoconazole [28]. In recent study, all isolates were susceptible in both 
groups; isolates from HIV-infected patients showed MIC values  between 0.03 - 
4.0 μg/ml while the MIC values ranged from 0.03-0.25 μg/ml for the isolates 
from control patients [29]. Also it was found that 88% of C. albicans isolates 
were sensitive to ketoconazole [9]. Our result was also in agreement with 
results reported previously [30], these results showed that  90% of C. albicans 
were susceptible to Ketoconazole and had MIC <0.125 μg/ml). 
The in vitro susceptibility of C. albicans to Tterbinafine and Ketoconazole has 
already been described by different investigators [12,17]. However, there is no 
information available from Palestine, in this respect as ecology of Candida 
species and the epidemiology of candidiasis are different in many parts of the 
world, it is important to know whether these differences also reflect variations 
in susceptibilities to antifungal agents such as Terbinafine an Ketoconazole 
[12,17]. This is the first report of in vitro antifungal susceptibility data to be 
published from Palestine against clinical isolates of C. albicans. Therefore 
investigations concerning its antifungal activities in vivo against such organism 
should be pursued. So availability of sensitive and highly  accurate antifungal 
susceptibility testing methods, can permit analysis of data in vitro and with 
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outcome in vivo, important  to assist physician for making appropriate drug 
choices and patient management decision. These data indicated that Terbinafine 
and Ketoconazole are still active against C. albicans and may therefore have 
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